



## **IDEAYA Biosciences to Present at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference**

**San Francisco and San Diego, Jan. 4, 2018** — IDEAYA Biosciences, an oncology-focused biotechnology company committed to the discovery of breakthrough small-molecule synthetic lethality and immuno-oncology therapies, today announced that Yujiro S. Hata, chief executive officer of IDEAYA, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco at 1:30 p.m. PT on Wednesday, January 10.

### **About IDEAYA Biosciences**

IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and San Diego, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery. For more information, please visit [www.ideayabio.com](http://www.ideayabio.com).

### **Investor and Media Contact:**

IDEAYA Biosciences  
Tim Smith  
SVP, Head of Corporate Development  
(650) 557-2689  
[tsmith@ideayabio.com](mailto:tsmith@ideayabio.com)